Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Neoplasms of the CNS

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 98 articles: HTML format

Single Articles

January 2025
1. ORR BA
   Transcription Factor Fingerprint Provides Clues for Brain Tumor Cell of Origin.
   Cancer Res. 2025;85:195-196.
   PubMed     Abstract available
   
   
   
2. JESSA S, De Cola A, Chandarana B, McNicholas M, et al
   FOXR2 Targets LHX6+/DLX+ Neural Lineages to Drive Central Nervous System Neuroblastoma.
   Cancer Res. 2025;85:231-250.
   PubMed     Abstract available
   
   
   
3. NINOMIYA T, Kemmotsu N, Mukohara F, Magari M, et al
   Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy.
   Cancer Res. 2025 Jan 13. doi: 10.1158/0008-5472.CAN-24-2274.
   PubMed     Abstract available
   
   
   December 2024
4. DRUCKER KL, Jenkins RB, Schramek D
   Switching Drivers: Epigenetic Rewiring to Genetic Progression in Glioma.
   Cancer Res. 2024 Dec 30. doi: 10.1158/0008-5472.CAN-24-4907.
   PubMed     Abstract available
   
   
   
5. WU CY, Chen Y, Lin YJ, Wei KC, et al
   Tumor-Associated Microglia Secrete Extracellular ATP to Support Glioblastoma Progression.
   Cancer Res. 2024;84:4017-4030.
   PubMed     Abstract available
   
   
   November 2024
6. ZHOU Z, Yin X, Sun H, Lu J, et al
   PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis.
   Cancer Res. 2024 Nov 21. doi: 10.1158/0008-5472.CAN-24-1412.
   PubMed     Abstract available
   
   
   
7. IZAR B, Kim M
   Peritumoral Venous Vessels: Autobahn and Portal for T cells to Melanoma Brain Metastasis.
   Cancer Res. 2024 Nov 8. doi: 10.1158/0008-5472.CAN-24-4054.
   PubMed     Abstract available
   
   
   
8. CHEN X, Geng Y, Wei G, He D, et al
   Neural Circuitries between the Brain and Peripheral Solid Tumors.
   Cancer Res. 2024;84:3509-3521.
   PubMed     Abstract available
   
   
   October 2024
9. CHEN D, Le SB, Manektalia H, Liu T, et al
   The EP3-ZNF488 Axis Promotes Self-Renewal of Glioma Stem-like Cells to Induce Resistance to Tumor Treating Fields.
   Cancer Res. 2024 Oct 16. doi: 10.1158/0008-5472.CAN-23-3643.
   PubMed     Abstract available
   
   
   
10. RIMKUS TK, Carpenter RL, Sirkisoon S, Zhu D, et al
    Editor's Note: Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44.
    Cancer Res. 2024;84:3310.
    PubMed    
    
    
    September 2024
11. PANG L, Zhou F, Chen P
    Lipid-laden macrophages recycle myelin to feed glioblastoma.
    Cancer Res. 2024 Sep 18. doi: 10.1158/0008-5472.CAN-24-3362.
    PubMed     Abstract available
    
    
    August 2024
12. LEE C, Yu D, Kim HS, Kim KS, et al
    Galectin-9 Mediates the Functions of Microglia in the Hypoxic Brain Tumor Microenvironment.
    Cancer Res. 2024 Aug 29. doi: 10.1158/0008-5472.CAN-23-3878.
    PubMed     Abstract available
    
    
    
13. MACLEOD G, Molaei F, Haider S, Almeida MP, et al
    Fitness Screens Map State-Specific Glioblastoma Stem Cell Vulnerabilities.
    Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-4024.
    PubMed     Abstract available
    
    
    
14. JIAO M, Pirozzi CJ, Yu C, Bao X, et al
    Targeting Catechol-O-Methyltransferase Induces Mitochondrial Dysfunction and Enhances the Efficacy of Radiotherapy in Glioma.
    Cancer Res. 2024 Aug 1. doi: 10.1158/0008-5472.CAN-24-0134.
    PubMed     Abstract available
    
    
    July 2024
15. NAIR NU, Schaffer AA, Gertz EM, Cheng K, et al
    Chromosome 7 gain compensates for chromosome 10 loss in glioma.
    Cancer Res. 2024 Jul 30. doi: 10.1158/0008-5472.CAN-24-1366.
    PubMed     Abstract available
    
    
    April 2024
16. LOW JCM, Cao J, Hesse F, Wright AJ, et al
    Deuterium metabolic imaging differentiates glioblastoma metabolic subtypes and detects early response to chemoradiotherapy.
    Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2552.
    PubMed     Abstract available
    
    
    March 2024
17. HWANG GH, Pazyra-Murphy MF, Seo HS, Dhe-Paganon S, et al
    A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma.
    Cancer Res. 2024;84:872-886.
    PubMed     Abstract available
    
    
    February 2024
18. LI J, Shih LK, Brat DJ
    Integrated Proteogenomics Uncover Mechanisms of Glioblastoma Evolution, Pointing to Novel Therapeutic Targets.
    Cancer Res. 2024 Feb 8. doi: 10.1158/0008-5472.CAN-24-0452.
    PubMed     Abstract available
    
    
    January 2024
19. UNDERHILL HR, Karsy M, Davidson CJ, Hellwig S, et al
    Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas.
    Cancer Res. 2024 Jan 25. doi: 10.1158/0008-5472.CAN-23-2557.
    PubMed     Abstract available
    
    
    
20. ZHAO D, Verhaak RGW
    Defining the role of extrachromosomal DNA amplifications in medulloblastoma.
    Cancer Res. 2024 Jan 4. doi: 10.1158/0008-5472.CAN-23-4025.
    PubMed     Abstract available
    
    
    December 2023
21. MALTA TM, Sabedot TS, Morosini NS, Datta I, et al
    The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen.
    Cancer Res. 2023 Dec 20. doi: 10.1158/0008-5472.CAN-23-2093.
    PubMed     Abstract available
    
    
    
22. WANG D, Yan K, Yu H, Li H, et al
    Fimepinostat impairs NF-kappaB and PI3K/AKT signaling and enhances gemcitabine efficacy in H3K27M-mutated diffuse intrinsic pontine glioma.
    Cancer Res. 2023 Dec 14. doi: 10.1158/0008-5472.CAN-23-0394.
    PubMed     Abstract available
    
    
    November 2023
23. GUO X, Qiu W, Wang C, Qi Y, et al
    Neuronal activity promotes glioma progression by inducing proneural-to-mesenchymal transition in glioma stem cells.
    Cancer Res. 2023 Nov 14. doi: 10.1158/0008-5472.CAN-23-0609.
    PubMed     Abstract available
    
    
    September 2023
24. YIN J, Seo Y, Rhim J, Jin X, et al
    Crosstalk between PARN and EGFR-STAT3 Signaling Facilitates Self-Renewal and Proliferation of Glioblastoma Stem Cells.
    Cancer Res. 2023 Sep 25. doi: 10.1158/0008-5472.CAN-22-3965.
    PubMed     Abstract available
    
    
    May 2023
25. MONDAL I, Das O, Sun R, Gao J, et al
    PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma.
    Cancer Res. 2023 May 23:CAN-22-3382. doi: 10.1158/0008-5472.CAN-22-3382.
    PubMed     Abstract available
    
    
    
26. JACKSON ER, Duchatel RJ, Staudt DE, Persson ML, et al
    ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
    Cancer Res. 2023 May 17:OF1-OF17. doi: 10.1158/0008-5472.CAN-23-0186.
    PubMed     Abstract available
    
    
    
27. BAYIK D, Bartels CF, Lovrenert K, Watson DC, et al
    Correction: Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets.
    Cancer Res. 2023;83:1757.
    PubMed    
    
    
    
28. JACKSON ER, Duchatel RJ, Staudt DE, Persson ML, et al
    ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
    Cancer Res. 2023 May 5:CAN-23-0186. doi: 10.1158/0008-5472.CAN-23-0186.
    PubMed     Abstract available
    
    
    April 2023
29. GUETTA-TERRIER C, Karambizi D, Akosman B, Zepecki JP, et al
    Chi3l1 is a modulator of glioma stem cell states and a therapeutic target in glioblastoma.
    Cancer Res. 2023 Apr 27:CAN-21-3629. doi: 10.1158/0008-5472.CAN-21-3629.
    PubMed     Abstract available
    
    
    
30. MIRZAEI R, D'Mello C, Liu M, Nikolic A, et al
    Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor-Initiating Cells.
    Cancer Res. 2023 Apr 17:OF1-OF17. doi: 10.1158/0008-5472.CAN-22-3004.
    PubMed     Abstract available
    
    
    
31. KARREMAN MA, Bauer AT, Solecki G, Berghoff AS, et al
    Active Remodeling of Capillary Endothelium via Cancer Cell-Derived MMP9 Promotes Metastatic Brain Colonization.
    Cancer Res. 2023;83:1299-1314.
    PubMed     Abstract available
    
    
    March 2023
32. ZAMLER DB, Hu J
    Primitive Oligodendrocyte Precursor Cells Are Highly Susceptible to Gliomagenic Transformation.
    Cancer Res. 2023;83:807-808.
    PubMed     Abstract available
    
    
    
33. PINE AR, Cirigliano SM, Singhania R, Nicholson J, et al
    Microenvironment-driven dynamic chromatin changes in glioblastoma recapitulate early neural development at single-cell resolution.
    Cancer Res. 2023 Mar 6:CAN-22-2872. doi: 10.1158/0008-5472.CAN-22-2872.
    PubMed     Abstract available
    
    
    February 2023
34. GALLON J, Rodriguez-Calero A, Benjak A, Akhoundova D, et al
    DNA methylation landscapes of prostate cancer brain metastasis are shaped by early driver genetic alterations.
    Cancer Res. 2023 Feb 7:CAN-22-2236. doi: 10.1158/0008-5472.CAN-22-2236.
    PubMed     Abstract available
    
    
    January 2023
35. ZHAO M, Li Y, Lu C, Ding F, et al
    PGC-1alpha degradation suppresses mitochondrial biogenesis to confer radiation resistance in glioma.
    Cancer Res. 2023 Jan 25:CAN-22-3083. doi: 10.1158/0008-5472.CAN-22-3083.
    PubMed     Abstract available
    
    
    
36. VERMA R, Chen X, Xin D, Luo Z, et al
    Olig1/2-expressing intermediate lineage progenitors are predisposed to PTEN/p53-loss-induced gliomagenesis and harbor specific therapeutic vulnerabilities.
    Cancer Res. 2023 Jan 12:CAN-22-1577. doi: 10.1158/0008-5472.CAN-22-1577.
    PubMed     Abstract available
    
    
    
37. WU M, Wu L, Wu W, Zhu M, et al
    Phagocytosis of glioma cells enhances the immunosuppressive phenotype of bone marrow-derived macrophages.
    Cancer Res. 2023 Jan 9:CAN-22-1570. doi: 10.1158/0008-5472.CAN-22-1570.
    PubMed     Abstract available
    
    
    December 2022
38. AGNIHOTRI S, Golbourn B, Huang X, Remke M, et al
    Correction: PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma.
    Cancer Res. 2022;82:4695.
    PubMed    
    
    
    November 2022
39. PIERI V, Gallotti AL, Drago D, Cominelli M, et al
    Aberrant L-Fucose accumulation and increased core fucosylation are metabolic liabilities in mesenchymal glioblastoma.
    Cancer Res. 2022 Nov 21:CAN-22-0677. doi: 10.1158/0008-5472.CAN-22-0677.
    PubMed     Abstract available
    
    
    October 2022
40. KUZUOGLU-OZTURK D, Aksoy O, Schmidt C, Lea R, et al
    N-myc mediated translation control is a therapeutic vulnerability in medulloblastoma.
    Cancer Res. 2022 Oct 20. pii: 709870. doi: 10.1158/0008-5472.CAN-22-0945.
    PubMed     Abstract available
    
    
    
41. MOSER JC, Salvador E, Deniz K, Swanson K, et al
    The Mechanisms of Action of Tumor Treating Fields.
    Cancer Res. 2022;82:3650-3658.
    PubMed     Abstract available
    
    
    
42. BORGENVIK A, Holmberg KO, Bolin S, Zhao M, et al
    Dormant SOX9-positive cells facilitate MYC-driven recurrence of medulloblastoma.
    Cancer Res. 2022 Oct 11. pii: 709709. doi: 10.1158/0008-5472.CAN-22-2108.
    PubMed     Abstract available
    
    
    September 2022
43. BAYIK D, Bartels CF, Lovrenert K, Watson DC, et al
    Distinct cell adhesion signature defines glioblastoma myeloid-derived suppressor cell subsets.
    Cancer Res. 2022 Sep 20. pii: 709287. doi: 10.1158/0008-5472.CAN-21-3840.
    PubMed     Abstract available
    
    
    
44. GAN T, Wang Y, Xie M, Wang Q, et al
    MEX3A impairs DNA mismatch repair signaling and mediates acquired temozolomide resistance in glioblastoma.
    Cancer Res. 2022 Sep 16. pii: 709224. doi: 10.1158/0008-5472.CAN-22-2036.
    PubMed     Abstract available
    
    
    
45. SHIELDS JA, Meier SR, Bandi M, Mulkearns-Hubert EE, et al
    VRK1 is a Synthetic Lethal Target in VRK2-deficient Glioblastoma.
    Cancer Res. 2022 Sep 7. pii: 709105. doi: 10.1158/0008-5472.CAN-21-4443.
    PubMed     Abstract available
    
    
    August 2022
46. HESSE F, Wright AJ, Somai V, Bulat F, et al
    Imaging glioblastoma response to radiotherapy using 2H magnetic resonance spectroscopy measurements of fumarate metabolism.
    Cancer Res. 2022 Aug 16. pii: 707755. doi: 10.1158/0008-5472.CAN-22-0101.
    PubMed     Abstract available
    
    
    July 2022
47. LI Y, Wang T, Wan Q, Wang Q, et al
    TRAF4 maintains deubiquitination of Caveolin-1 to drive glioblastoma stemness and Temozolomide resistance.
    Cancer Res. 2022 Jul 27. pii: 707286. doi: 10.1158/0008-5472.CAN-21-3882.
    PubMed     Abstract available
    
    
    
48. DEVAN SP, Jiang X, Luo G, Xie J, et al
    Selective cell size MRI differentiates brain tumors from radiation necrosis.
    Cancer Res. 2022 Jul 25. pii: 707206. doi: 10.1158/0008-5472.CAN-21-2929.
    PubMed     Abstract available
    
    
    
49. LI D, Zhang Q, Li L, Chen K, et al
    beta2-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages.
    Cancer Res. 2022 Jul 15. pii: 707040. doi: 10.1158/0008-5472.CAN-22-0507.
    PubMed     Abstract available
    
    
    
50. GUO D, Xiao J, Liang J, Fan J, et al
    CDK4/6 inhibition enhances oncolytic virus efficacy by potentiating tumor-selective cell killing and T cell activation in refractory glioblastoma.
    Cancer Res. 2022 Jul 6. pii: 706877. doi: 10.1158/0008-5472.CAN-21-3656.
    PubMed     Abstract available
    
    
    June 2022
51. YI J, Kim B, Shi X, Zhan X, et al
    PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma.
    Cancer Res. 2022 Jun 22. pii: 705063. doi: 10.1158/0008-5472.CAN-21-4313.
    PubMed     Abstract available
    
    
    
52. KARLOW JA, Devarakonda S, Xing X, Jang HS, et al
    Developmental pathways are epigenetically reprogrammed during lung cancer brain metastasis.
    Cancer Res. 2022 Jun 15. pii: 704908. doi: 10.1158/0008-5472.CAN-21-4160.
    PubMed     Abstract available
    
    
    May 2022
53. BONFILL-TEIXIDOR E, Iurlaro R, Handl C, Wichmann J, et al
    Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis.
    Cancer Res. 2022 May 18. pii: 699020. doi: 10.1158/0008-5472.CAN-21-4152.
    PubMed     Abstract available
    
    
    
54. ZHANG B, Peng H, Zhou M, Bao L, et al
    Targeting BCAT1 combined with alpha-ketoglutarate triggers metabolic synthetic lethality in glioblastoma.
    Cancer Res. 2022 May 2. pii: 696261. doi: 10.1158/0008-5472.CAN-21-3868.
    PubMed     Abstract available
    
    
    March 2022
55. GABRIEL NN, Balaji K, Jayachandran K, Inkman M, et al
    Loss of H3K27 trimethylation promotes radiotherapy resistance in medulloblastoma and induces an actionable vulnerability to BET inhibition.
    Cancer Res. 2022 Mar 22. pii: 682339. doi: 10.1158/0008-5472.CAN-21-0871.
    PubMed     Abstract available
    
    
    
56. BINDER ZA, O'Rourke DM
    Glioblastoma: The Current State of Biology and Therapeutic Strategies.
    Cancer Res. 2022;82:769-772.
    PubMed     Abstract available
    
    
    February 2022
57. AUZMENDI-IRIARTE J, Otaegi-Ugartemendia M, Carrasco-Garcia E, Azkargorta M, et al
    Chaperone-mediated autophagy controls proteomic and transcriptomic pathways to maintain glioma stem cell activity.
    Cancer Res. 2022 Feb 7. pii: 0008-5472.CAN-21-2161.
    PubMed     Abstract available
    
    
    December 2021
58. SEN A, Prager BC, Zhong C, Park D, et al
    Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma.
    Cancer Res. 2021 Dec 13. pii: 0008-5472.CAN-21-0810.
    PubMed     Abstract available
    
    
    
59. MAZE EA, Agit B, Reeves S, Hilton DA, et al
    Human endogenous retrovirus type K promotes proliferation and confers sensitivity to anti-retroviral drugs in Merlin-negative schwannoma and meningioma.
    Cancer Res. 2021 Dec 1. pii: 0008-5472.CAN-20-3857.
    PubMed     Abstract available
    
    
    November 2021
60. YANG Z, Hu N, Wang W, Hu W, et al
    Loss of FBXW7 correlates with increased IDH1 expression in glioma and enhances IDH1-mutant cancer cell sensitivity to radiation.
    Cancer Res. 2021 Nov 4. pii: 0008-5472.CAN-21-0384.
    PubMed     Abstract available
    
    
    
61. XING F, Liu Y, Wu SY, Wu K, et al
    Correction: Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.
    Cancer Res. 2021;81:5582.
    PubMed    
    
    
    September 2021
62. FLETCHER-SANANIKONE E, Kanji S, Tomimatsu N, Macedo Di Cristofaro LF, et al
    Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence.
    Cancer Res. 2021 Sep 27. pii: 0008-5472.CAN-21-0752.
    PubMed     Abstract available
    
    
    
63. ANSARI KI, Bhan A, Saotome M, Tyagi A, et al
    Autocrine GMCSF Signaling Contributes to Growth of HER2(+) Breast Leptomeningeal Carcinomatosis.
    Cancer Res. 2021;81:4723-4735.
    PubMed     Abstract available
    
    
    
64. LOPES-RAMOS CM, Belova T, Brunner TH, Ben Guebila M, et al
    Regulatory network of PD1 signaling is associated with prognosis in glioblastoma multiforme.
    Cancer Res. 2021 Sep 7. pii: 0008-5472.CAN-21-0730.
    PubMed     Abstract available
    
    
    
65. FAURE C, Djerbi-Bouillie R, Domingot A, Bouzinba-Segard H, et al
    Allosteric inhibition of HER2 by Moesin-mimicking compounds targets HER2-positive cancers and brain metastases.
    Cancer Res. 2021 Sep 7. pii: 0008-5472.CAN-21-0162.
    PubMed     Abstract available
    
    
    
66. ANDERSON NM, Qin X, Finan JM, Lam A, et al
    Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma.
    Cancer Res. 2021;81:4417-4430.
    PubMed     Abstract available
    
    
    August 2021
67. WU AH, Fruin S, Larson TV, Tseng CC, et al
    Association between Airport-Related Ultrafine Particles and Risk of Malignant Brain Cancer: A Multiethnic Cohort Study.
    Cancer Res. 2021;81:4360-4369.
    PubMed     Abstract available
    
    
    July 2021
68. AOKI K, Suzuki H, Yamamoto T, Yamamoto KN, et al
    Mathematical modeling and mutational analysis reveal optimal therapy to prevent malignant transformation in grade II IDH-mutant gliomas.
    Cancer Res. 2021 Jul 31. pii: 0008-5472.CAN-21-0985.
    PubMed     Abstract available
    
    
    
69. NAJM P, Zhao P, Steklov M, Sewduth RN, et al
    Loss-of-function mutations in TRAF7 and KLF4 cooperatively activate RAS-like GTPase signaling and promote meningioma development.
    Cancer Res. 2021 Jul 2. pii: 0008-5472.CAN-20-3669.
    PubMed     Abstract available
    
    
    June 2021
70. BHAN A, Ansari KI, Chen MY, Jandial R, et al
    Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2(+) Breast Leptomeningeal Carcinomatosis Growth via Inhibition of GMCSF Expression.
    Cancer Res. 2021;81:3200-3214.
    PubMed     Abstract available
    
    
    
71. MO J, Liu F, Sun X, Huang H, et al
    Inhibition of the FACT Complex Targets Aberrant Hedgehog Signaling and Overcomes Resistance to Smoothened Antagonists.
    Cancer Res. 2021;81:3105-3120.
    PubMed     Abstract available
    
    
    May 2021
72. MA R, Lu T, Li Z, Teng KY, et al
    An oncolytic virus expressing IL-15/IL-15Ralpha combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma.
    Cancer Res. 2021 May 18. pii: 0008-5472.CAN-21-0035.
    PubMed     Abstract available
    
    
    
73. MA T, Hu C, Lal B, Zhou W, et al
    Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells.
    Cancer Res. 2021;81:2457-2469.
    PubMed     Abstract available
    
    
    April 2021
74. GAO M, Fu Y, Zhou W, Gui G, et al
    EGFR Activates a TAZ-driven Oncogenic Program in Glioblastoma.
    Cancer Res. 2021 Apr 28. pii: 0008-5472.CAN-20-2773.
    PubMed     Abstract available
    
    
    
75. FILIPPOVA N, Yang X, Ananthan S, Calano J, et al
    Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors.
    Cancer Res. 2021;81:2220-2233.
    PubMed     Abstract available
    
    
    
76. LI M, Kirtane AR, Kiyokawa J, Nagashima H, et al
    Local Targeting of NAD(+) Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma.
    Cancer Res. 2021;81:1922.
    PubMed    
    
    
    March 2021
77. JALALI A, Yu K, Beechar V, Bosquez Huerta N, et al
    POT1 regulates proliferation and confers sexual dimorphism in glioma.
    Cancer Res. 2021 Mar 29. pii: 0008-5472.CAN-20-3755.
    PubMed     Abstract available
    
    
    February 2021
78. SEGURA-COLLAR B, Garranzo-Asensio M, Herranz B, Hernandez-SanMiguel E, et al
    Tumor-derived pericytes driven by EGFR mutations govern the vascular and immune microenvironment of gliomas.
    Cancer Res. 2021 Feb 16. pii: 0008-5472.CAN-20-3558.
    PubMed     Abstract available
    
    
    
79. DAY EK, Zhong Q, Purow B, Lazzara MJ, et al
    Data-driven computational modeling identifies determinants of glioblastoma response to SHP2 inhibition.
    Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-1756.
    PubMed     Abstract available
    
    
    
80. SUTCLIFFE MD, Galvao RP, Wang L, Kim J, et al
    Premalignant oligodendrocyte precursor cells stall in a heterogeneous state of replication stress prior to gliomagenesis.
    Cancer Res. 2021 Feb 2. pii: 0008-5472.CAN-20-1037.
    PubMed     Abstract available
    
    
    January 2021
81. OH H, Hwang I, Jang JY, Wu L, et al
    Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling.
    Cancer Res. 2021 Jan 28. pii: 0008-5472.CAN-20-1810.
    PubMed     Abstract available
    
    
    
82. BERG TJ, Marques C, Pantazopoulou V, Johansson E, et al
    The irradiated brain microenvironment supports glioma stemness and survival via astrocyte-derived Transglutaminase 2.
    Cancer Res. 2021 Jan 22. pii: 0008-5472.CAN-20-1785.
    PubMed     Abstract available
    
    
    
83. NOR C, Ramaswamy V
    Next-Generation Profiling of Medulloblastoma: Old Drugs Are an Elegant Weapon in a Civilized Age.
    Cancer Res. 2021;81:264-265.
    PubMed     Abstract available
    
    
    December 2020
84. NEY GM, McKay L, Koschmann C, Mody R, et al
    The Emerging Role of Ras Pathway Signaling in Pediatric Cancer.
    Cancer Res. 2020;80:5155-5163.
    PubMed     Abstract available
    
    
    November 2020
85. LI J, Liao T, Liu H, Yuan H, et al
    Hypoxic glioma stem cell-derived exosomes containing Linc01060 promote progression of glioma by regulating the MZF1/c-Myc/HIF-1alpha.
    Cancer Res. 2020 Nov 6. pii: 0008-5472.CAN-20-2270.
    PubMed     Abstract available
    
    
    October 2020
86. SARMIENTO SOTO M, Larkin JR, Martin C, Khrapitchev AA, et al
    STAT3-mediated astrocyte reactivity associated with brain metastasis contributes to neurovascular dysfunction.
    Cancer Res. 2020 Oct 26. pii: 0008-5472.CAN-20-2251.
    PubMed     Abstract available
    
    
    
87. RESTALL IJ, Cseh O, Richards LM, Pugh TJ, et al
    Brain tumor stem cell dependence on glutaminase reveals a metabolic vulnerability through the amino acid deprivation response pathway.
    Cancer Res. 2020 Oct 26. pii: 0008-5472.CAN-19-3923.
    PubMed     Abstract available
    
    
    
88. TATEISHI K, Miyake Y, Kawazu M, Sasaki N, et al
    A hyperactive RelA/p65-hexokinase 2 signaling axis drives primary central nervous system lymphoma.
    Cancer Res. 2020 Oct 16. pii: 0008-5472.CAN-20-2425.
    PubMed     Abstract available
    
    
    
89. RUSERT JM, Juarez EF, Brabetz S, Jensen J, et al
    Functional precision medicine identifies new therapeutic candidates for medulloblastoma.
    Cancer Res. 2020 Oct 12. pii: 0008-5472.CAN-20-1655.
    PubMed     Abstract available
    
    
    
90. VOLI F, Valli E, Lerra L, Kimpton K, et al
    Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion.
    Cancer Res. 2020;80:4129-4144.
    PubMed     Abstract available
    
    
    September 2020
91. LI M, Kirtane AR, Kiyokawa J, Nagashima H, et al
    Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1094.
    PubMed     Abstract available
    
    
    August 2020
92. DUNCAN RM, Reyes L, Moats K, Robinson RM, et al
    ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors.
    Cancer Res. 2020;80:3279-3291.
    PubMed     Abstract available
    
    
    July 2020
93. MONJE M
    Synaptic Communication in Brain Cancer.
    Cancer Res. 2020;80:2979-2982.
    PubMed     Abstract available
    
    
    
94. WU F, Zhang C, Zhao C, Wu H, et al
    Prostaglandin E1 Inhibits GLI2 Amplification-Associated Activation of the Hedgehog Pathway and Drug Refractory Tumor Growth.
    Cancer Res. 2020;80:2818-2832.
    PubMed     Abstract available
    
    
    April 2020
95. LOPEZ-BERTONI H, Kotchetkov IS, Mihelson N, Lal B, et al
    A Sox2:miR-486-5p Axis Regulates Survival of GBM Cells by Inhibiting Tumor Suppressor Networks.
    Cancer Res. 2020;80:1644-1655.
    PubMed     Abstract available
    
    
    
96. CHANDRA A, Jahangiri A, Chen W, Nguyen AT, et al
    Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
    Cancer Res. 2020;80:1498-1511.
    PubMed     Abstract available
    
    
    March 2020
97. TAN AW, Weljie AM
    Metabolite Imaging at the Margin: Visualizing Metabolic Tumor Gradients Using Mass Spectrometry.
    Cancer Res. 2020;80:1231-1233.
    PubMed     Abstract available
    
    
    February 2020
98. HEBERT JD, Myers SA, Naba A, Abbruzzese G, et al
    Proteomic profiling of the ECM of xenograft breast cancer metastases in different organs reveals distinct metastatic niches.
    Cancer Res. 2020 Feb 4. pii: 0008-5472.CAN-19-2961.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.